Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: Henry Niman who wrote (2836)	11/16/1997 9:58:00 AM
From: STANLEY COHEN	Respond to of 6136

To All: Please note that 8 insiders sold 181,100 shares of AGPH between 10/10/97 & 10/24/97 @ $52.04. If anyone has contacts with management at AGPH, prehaps one could find out what is going on. STANLEY COHEN

To: Henry Niman who wrote (2836)	11/16/1997 1:52:00 PM
From: JOHN W.	Read Replies (3) \| Respond to of 6136

This has already been proven false with Crixivan. I will find MRK's press release/article, but it was around 80% remained undetectable after 30 months on Indinavir, there are smaller groups that have remained undetectable longer. I will post the articles as soon as I find them for your review.

To: Henry Niman who wrote (2836)	11/16/1997 3:47:00 PM
From: Oliver & Co	Respond to of 6136

Revised HIV Treatment Guidelines Available November 13, 1997 -------------------------------------------------------------------------------- Revised Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents are now available on the Web site of the HIV/AIDS Treatment Information Service (ATIS) and can be reached at hivatis.org The Guidelines were developed by the Panel on Clinical Practices for the Treatment of HIV Infection, which was convened jointly by the Department of Health and Human Services (DHHS) and the Henry J. Kaiser Family Foundation. The Panel was charged with developing recommendations for the clinical use of antiretroviral drugs and laboratory monitoring methods in the treatment of HIV-infected individuals. These recommendations were based in part on a companion document, Report of the NIH Panel to Define Principles of Therapy of HIV Infection. HHS released the draft Guidelines to the public in June and requested comments. The revised Guidelines are based on feedback received during the 30-day comment period and further discussions among Panel members. As research provides new information about the treatment of HIV disease, the Guidelines on the ATIS Web site will undergo further revision to include state-of-the-art knowledge. The current revised Guidelines are being submitted to the Centers for Disease Control and Prevention (CDC) to be considered for publication in the Morbidity and Mortality Weekly Report. The Panel is co-chaired by Anthony S. Fauci, M.D., director of the National Institute of Allergy and Infectious Diseases, National Institutes of Health, and John G. Bartlett, M.D. Dr. Bartlett is professor of medicine and chief of infectious diseases at Johns Hopkins University School of Medicine. The Panel also includes federal, private sector and academic experts in the clinical treatment and care of HIV-infected people, as well as representatives of AIDS interest groups, health policy groups and payer organizations.